Advertisement
JNJ vs ZTS
Which Stock Would AI Choose? Johnson & Johnson (JNJ) vs. Zoetis (ZTS) Stock Comparison
Key Takeaways
- JNJ has delivered strong year-to-date gains of approximately 17.6%, significantly outperforming ZTS's roughly -8% decline amid recent market pressures.
- Recent FDA approvals for JNJ's TECNIS PureSee lens and pipeline advancements like Tecvayli have bolstered sentiment, while ZTS faces scrutiny over growth slowdowns and share price weakness.
- JNJ offers a higher dividend yield of 2.15% with lower volatility (beta 0.33), appealing to stability-focused investors, compared to ZTS's 1.84% yield and beta of 0.95.
- Both stocks trade at comparable trailing P/E ratios around 20-22x, but JNJ's diversified healthcare exposure provides broader resilience versus ZTS's animal health niche.
- JNJ's market cap exceeds $580B, dwarfing ZTS's $50B, reflecting greater scale and liquidity in stock comparisons.
Introduction
Johnson & Johnson (JNJ) and Zoetis (ZTS) represent distinct facets of the healthcare sector, with JNJ spanning pharmaceuticals, medtech, and consumer health, and ZTS leading in animal health solutions. This stock comparison evaluates their relative performance, business models, and market positioning amid recent volatility. Traders seeking defensive plays may favor JNJ's stability, while growth-oriented investors might eye ZTS's innovation in veterinary care. Understanding these dynamics aids in assessing sector exposure and relative performance in the current environment.
JNJ Overview and Recent Performance
Johnson & Johnson (JNJ), a diversified healthcare giant, operates in innovative medicine and medtech segments, offering products in oncology, immunology, surgery, and vision care. Trading around $242 with a market cap over $580 billion, JNJ has shown resilience, posting YTD returns of 17.6% and 52.8% over one year, far outpacing broader indices. Recent weeks have seen positive momentum from FDA approval of the TECNIS PureSee intraocular lens, enhancing its vision portfolio, alongside analyst price target hikes and EU filings for Tecvayli in multiple myeloma. These developments, coupled with a low beta of 0.33, have supported sentiment amid market fluctuations, underscoring JNJ's defensive positioning and pipeline strength.
ZTS Overview and Recent Performance
Zoetis (ZTS), the world's leading animal health company, develops vaccines, medicines, diagnostics, and precision tools for companion animals and livestock. At approximately $115 and a $50 billion market cap, ZTS has faced headwinds, with YTD declines around -8% and a one-year drop of over 27%, hitting 52-week lows near $115. Recent market activity reflects concerns over growth pipeline scrutiny, U.S. companion animal softness, and stake sales by investors like Jensen. Despite acquisitions like Neogen's genomics business for $160 million and approvals for OA pain therapies Lenivia and Portela, share price weakness persists, influenced by competitive pressures and fewer veterinary visits, contrasting its higher beta of 0.95.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases a curated selection of the platform's hundreds of AI trading bots, which analyze thousands of tickers using advanced machine learning for real-time signals across diverse strategies, timeframes, and assets like stocks, ETFs, and crypto. Only the highest-performing bots, adapted to current volatility and sector rotations, earn a spot here—boasting annualized returns up to 216%, win rates of 70-95%, profit factors reaching 9, and low drawdowns on model portfolios. Examples include semiconductor-focused agents with 70%+ win rates and multi-ticker trend followers exploiting dips in energy or aerospace. These bots employ technical patterns, fundamentals, hedging, and short-term momentum, with timeframes from 5 minutes to days. Explore Trending AI Robots to identify tools matching your style and market conditions.
Head-to-Head Comparison
JNJ and ZTS diverge in business models: JNJ's broad human healthcare diversification across pharma and devices contrasts ZTS's specialized animal health focus on pets and livestock, exposing the latter to veterinary demand cycles. Growth drivers for JNJ include oncology catalysts like Tecvayli and medtech innovations, while ZTS relies on precision diagnostics and pain therapies amid pipeline concerns. Recent momentum favors JNJ with steady gains versus ZTS's declines. Risk factors highlight JNJ's lower beta (0.33) and scale for stability, against ZTS's higher volatility (beta 0.95) and niche risks. Sector exposure positions JNJ as a healthcare staple, with market sentiment lifted by approvals, while ZTS grapples with growth doubts.
Tickeron AI Verdict
Tickeron’s AI currently favors JNJ over ZTS, driven by superior trend consistency, lower volatility, positive catalysts like recent FDA nods, and stronger relative positioning with robust YTD gains and analyst support. While ZTS holds undervaluation potential, its momentum fade reduces near-term probability of outperformance versus JNJ's stability in choppy markets.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is JNJ is a Hold and ZTS is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
JNJ’s FA Score shows that 3 FA rating(s) are green whileZTS’s FA Score has 2 green FA rating(s).
- JNJ’s FA Score: 3 green, 2 red.
- ZTS’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
JNJ’s TA Score shows that 3 TA indicator(s) are bullish while ZTS’s TA Score has 4 bullish TA indicator(s).
- JNJ’s TA Score: 3 bullish, 4 bearish.
- ZTS’s TA Score: 4 bullish, 6 bearish.
Price Growth
JNJ (@Pharmaceuticals: Major) experienced а -0.71% price change this week, while ZTS (@Pharmaceuticals: Generic) price change was +1.74% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -0.87%. For the same industry, the average monthly price growth was -3.24%, and the average quarterly price growth was +6.57%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +3.55%. For the same industry, the average monthly price growth was +3.94%, and the average quarterly price growth was -0.03%.
Reported Earning Dates
JNJ is expected to report earnings on Apr 14, 2026.
ZTS is expected to report earnings on May 07, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (-0.87% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
@Pharmaceuticals: Generic (+3.55% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
| JNJ | ZTS | JNJ / ZTS | |
| Capitalization | 581B | 50.5B | 1,150% |
| EBITDA | 41.1B | 4.07B | 1,010% |
| Gain YTD | 17.223 | -4.226 | -408% |
| P/E Ratio | 21.88 | 19.93 | 110% |
| Revenue | 94.2B | 9.47B | 995% |
| Total Cash | 20.1B | 2.31B | 870% |
| Total Debt | 47.9B | 9.24B | 519% |
JNJ | ZTS | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 60 | 7 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 23 Undervalued | 30 Undervalued | |
PROFIT vs RISK RATING 1..100 | 8 | 100 | |
SMR RATING 1..100 | 27 | 16 | |
PRICE GROWTH RATING 1..100 | 42 | 61 | |
P/E GROWTH RATING 1..100 | 77 | 85 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
JNJ's Valuation (23) in the Pharmaceuticals Major industry is in the same range as ZTS (30) in the Pharmaceuticals Generic industry. This means that JNJ’s stock grew similarly to ZTS’s over the last 12 months.
JNJ's Profit vs Risk Rating (8) in the Pharmaceuticals Major industry is significantly better than the same rating for ZTS (100) in the Pharmaceuticals Generic industry. This means that JNJ’s stock grew significantly faster than ZTS’s over the last 12 months.
ZTS's SMR Rating (16) in the Pharmaceuticals Generic industry is in the same range as JNJ (27) in the Pharmaceuticals Major industry. This means that ZTS’s stock grew similarly to JNJ’s over the last 12 months.
JNJ's Price Growth Rating (42) in the Pharmaceuticals Major industry is in the same range as ZTS (61) in the Pharmaceuticals Generic industry. This means that JNJ’s stock grew similarly to ZTS’s over the last 12 months.
JNJ's P/E Growth Rating (77) in the Pharmaceuticals Major industry is in the same range as ZTS (85) in the Pharmaceuticals Generic industry. This means that JNJ’s stock grew similarly to ZTS’s over the last 12 months.
| JNJ | ZTS | |
|---|---|---|
| RSI ODDS (%) | N/A | 1 day ago 55% |
| Stochastic ODDS (%) | 1 day ago 51% | 1 day ago 62% |
| Momentum ODDS (%) | 1 day ago 40% | 1 day ago 52% |
| MACD ODDS (%) | 1 day ago 50% | 1 day ago 69% |
| TrendWeek ODDS (%) | 1 day ago 40% | 1 day ago 57% |
| TrendMonth ODDS (%) | 1 day ago 42% | 1 day ago 63% |
| Advances ODDS (%) | 1 day ago 44% | 1 day ago 52% |
| Declines ODDS (%) | 4 days ago 41% | 15 days ago 58% |
| BollingerBands ODDS (%) | N/A | 1 day ago 59% |
| Aroon ODDS (%) | 1 day ago 33% | 1 day ago 65% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| TOPT | 29.98 | 0.30 | +1.01% |
| iShares Top 20 U.S. Stocks ETF | |||
| XLRE | 42.73 | 0.29 | +0.68% |
| State Street Real Estate Sel SectSPDRETF | |||
| IVVB | 32.83 | 0.09 | +0.27% |
| iShares Large Cap Deep Qt Ldrd ETF | |||
| XTL | 207.07 | 0.11 | +0.05% |
| State Street® SPDR® S&P® Telecom ETF | |||
| SIMS | 43.40 | N/A | N/A |
| Stt Strt®SPDR®S&PKenshoIntlgntStrctrETF | |||
ZTS and
Correlation & Price change
A.I.dvisor indicates that over the last year, ZTS has been loosely correlated with ELAN. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if ZTS jumps, then ELAN could also see price increases.
| Ticker / NAME | Correlation To ZTS | 1D Price Change % | ||
|---|---|---|---|---|
| ZTS | 100% | +0.20% | ||
| ELAN - ZTS | 52% Loosely correlated | -0.59% | ||
| VTRS - ZTS | 44% Loosely correlated | +0.26% | ||
| PRGO - ZTS | 41% Loosely correlated | -2.12% | ||
| PAHC - ZTS | 39% Loosely correlated | +0.78% | ||
| HLN - ZTS | 39% Loosely correlated | +0.40% | ||
More | ||||